Food and Staples Retailing Drug Retail

More

  • Over-the-counter Cialis?

    CNBC's Meg Tirrell reports Sanofi and Eli Lilly announced an agreement to pursue regulatory approval of an over-the-counter version of erectile dysfunction drug Cialis.

  • Zeroing in on rising drug prices

    CNBC's Meg Tirrell reports on the high cost of drug prices. Ezekial Emanuel, University of Pennsylvania; and Alex Brill, American Enterprise Institute, share their concerns and solutions for the issue.

  • Big move for PTC Therapeutics

    PTC Therapeutics skyrockets on a recommendation for approval in Europe for its Duchenne Muscular Dystrophy drug. CNBC's Meg Tirrell provides insight to the disease and treatment options. Shane Kovacs, PTC Therapeutics CFO, looks at the move in the stock.

  • Drug pricing in US versus world

    CNBC's Meg Tirrell reports why drugs in the U.S. versus the rest of the world are priced differently.

  • Ethics of 'right to try' laws

    Lawmakers in four states are considering changing the rules to allow terminally ill people access to experimental drugs before they have FDA approval. Kenneth Goodman, University of Miami, thinks this would be a bad bet for patients. Miles Nadal, MDC Partners Chairman & CEO, weighs in.

  • Pharma deal of the day

    CNBC's Meg Tirrell spoke with Merck Chairman & CEO Ken Frazier about the company's decision to sell its over the counter health care products to Bayer.

  • Barry Rosenstein, founder and managing partner of Jana Partners

    Walgreen's pending acquisition of Alliance Boots can mean lower taxes and a better company, according to activist investor Barry Rosenstein.

  • Eli Lilly acquires Novartis' animal health unit

    Eli Lilly Chairman & CEO John Lechleiter discusses his business' expansion of its animal health unit with the acquisition of Novartis' animal health business.

  • GlaxoSmithKline CEO: Widest portfolio of vaccines in world

    GlaxoSmithKline CEO Sir Andrew Witty, explains the large portfolio of vaccinations his company provides, and the value added from the company's acquisition of Novartis' vaccination business.

  • Novartis acquisition adds 'tremendous value'

    GlaxoSmithKline CEO Sir Andrew Witty, discusses the benefit to shareholders from his company's acquisition of Novartis' vaccination business, as well as its oncology unit.

  • Sarepta CEO 'optimistic' for muscle drug approval

    Sarepta Therapeutics CEO Chris Garabedian discusses the prospects for what he calls a "potential accelerated approval" for its Duchenne muscular dystrophy drug Eteplirsen.

  • Sarepta muscle drug faces challenges

    Sarepta Therapeutics is developing a drug for Duchenne muscular dystrophy. Its CEO Chris Garabedian discusses challenges the drug Eteplirsen has faced before the FDA.

  • Walgreens has come under pressure from an influential group of its shareholders, who want the US pharmacy chain to consider relocating to Europe, in what would be one of the largest tax inversions ever attempted. The FT reports.

  • Hep c breakthrough

    CNBC contributor Barbara Ryan provides insight into new guidelines from the World Health Organization, which strongly endorses two new hepatitis c drugs.

  • The U.K. and U.S. governments spent millions stockpiling a flu drug that is no better than paracetamol, according to a new report.

  • Ultragenyx CEO: Committed to helping patients pay for drugs

    Ultragenyx is now up around 150 percent from its IPO price. Its CEO Dr. Emil Kakkis provides insight on the development of its drugs, and just how committed the company is to treating patients with the diseases its drugs treat.

  • Injectable cholesterol drugs to face challenges

    FTI Consulting managing director Barbara Ryan provides insight on new drugs showing dramatic improvement in the standard of care for high cholesterol.

  • New class of cholesterol drugs

    CNBC's Dominic Chu reports on news out about a special new drug that could combat cholesterol.

  • CNBC's All-America survey: Obamacare & minimum wage

    CNBC's Steve Liesman reports how participants of CNBC's All-America Economic Survey view Obamacare, and raising the minimum wage.

  • CNBC's All-America survey: Marijuana views

    CNBC's Steve Liesman reports 56 percent of participants supported the legalization of marijuana in their town.